FT Options’s Regeneron Pharmaceuticals REGN Stock Holding History

FT Options’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	$29K	Buy	7,500 +2,500	+50%	+$1.19M	0.04%	151
2017 Q2	$288K	Buy	5,000 +2,500	+100%	+$1.09M	0.5%	46
2017 Q1	$61K	Sell	2,500 -53,900	-96%	-$20M	0.08%	141
2016 Q4	$71K	Buy	56,400 +9,400	+20%	+$3.57M	0.08%	121
2016 Q3	$777K	Buy	47,000 +21,500	+84%	+$8.62M	0.62%	39
2016 Q2	$418K	Buy	25,500 +12,000	+89%	+$4.62M	0.36%	55
2016 Q1	$33K	Sell	13,500 -37,200	-73%	-$15.3M	0.03%	191
2015 Q4	$3.93M	Buy	+50,700	New	+$27.5M	2.9%	7

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

FT Options's REGN Position: Q3 2017 in Review

FT Options increased its Regeneron Pharmaceuticals (REGN) stake by 90% in Q3 2017, buying an estimated $281K and bringing the position to 1,250 shares worth $559K. The position accounts for 0.84% of the portfolio, ranked #42.

FT Options first reported a position in REGN in Q4 2015 and has held it in 8 quarters since. The position peaked at $12M in Q1 2016. 605 funds tracked by Wall St. Rank hold REGN as of Q3 2017.

FT Options held 1,250 shares of Regeneron Pharmaceuticals worth $559K as of Q3 2017.
FT Options bought 591 Regeneron Pharmaceuticals shares in Q3 2017, an estimated $281K.
Regeneron Pharmaceuticals made up 0.84% of FT Options's portfolio in Q3 2017, its #42 holding.
FT Options first reported a position in Regeneron Pharmaceuticals in Q4 2015 and has held it in 8 quarters since.
FT Options's Regeneron Pharmaceuticals position peaked at $12M in Q1 2016.
605 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2017.

Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.